查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1417248

前列腺癌市場報告：2030 年趨勢、預測和競爭分析

Prostate Cancer Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

前列腺癌趨勢和預測

預計到 2030 年，全球前列腺癌市場將達到 194.7 億美元，2024 年至 2030 年複合年成長率為 8.7%。該市場的主要促進因素是前列腺癌發病率的增加導致對先進前列腺治療的需求增加、透過三期臨床試驗來推進前列腺癌治療、增加研發資金以及治療技術的進步。全球前列腺癌市場的未來看起來充滿希望，醫院藥局、藥局和零售藥局以及線上藥局市場充滿機會。

前列腺癌市場洞察

Lucintel 預計 AR標靶治療將在預測期內達到最高成長。

由於前列腺癌盛行率不斷上升、多種治療方案的可用性、技術發展、定製藥物和負擔得起的治療方法，亞太地區將在預測期內實現最高的成長預計

常問問題

Q.1 攝護腺癌的市場規模有多大？

A1. 到2030年，全球前列腺癌市場預計將達到194.7億美元。

Q.2 前列腺癌市場的成長預測為何：

A2. 2024年至2030年，全球前列腺癌市場預計將以8.7%的複合年成長率成長。

Q.3 影響攝護腺癌市場成長的關鍵因素有哪些：

A3. 該市場的主要驅動力是前列腺癌發生率不斷上升，這推動了對先進前列腺治療的需求，以及透過III期臨床試驗推進前列腺癌治療的進展，以及研發資金和治療進展的增加技術。

Q4.市場的主要細分市場是：

A4. 前列腺癌市場的未來看起來充滿希望，醫院藥局、藥局和零售藥局以及線上藥局市場都有機會。

Q5.市場的主要企業是：

A5. 與攝護腺癌相關的主要企業如下。

  • Ferring Pharmaceuticals
  • Johnson &Johnson
  • Merck
  • Pfizer
  • Sanofi
  • AbbVie
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Clovis Oncology

Q6.未來最大的細分市場是什麼？

A6.Lucintel 預計 AR標靶治療將在預測期內達到最高成長。

Q7. 未來五年預計哪些地區的市場成長最大？

A7.由於前列腺癌盛行率不斷上升、多種治療方案的可用性、技術發展、定製藥物和負擔得起的治療方法，亞太地區在預測期內將出現最高的成長率，預計將會成長。

Q8. 可以客製化報告嗎？

A8. 是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

目錄

第1章執行摘要

第2章全球前列腺癌市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球前列腺癌市場趨勢（2018-2023）與預測（2024-2030）
  • 按藥物類別分類的前列腺癌全球市場
    • 荷爾蒙ADT
    • AR標靶治療
    • 細胞毒性藥物
    • 骨轉移
    • 治療性疫苗
    • PARP抑制劑
    • 激酶抑制劑
    • PSMA 靶向放射性配體
  • 按分銷管道分類的前列腺癌市場
    • 醫院藥房
    • 藥局和零售藥局
    • 網路藥房

第4章 2018-2030年區域市場趨勢及預測分析

  • 按地區分類的前列腺癌市場
  • 北美前列腺癌市場
  • 歐洲攝護腺癌市場
  • 亞太地區前列腺癌市場
  • 其他地區前列腺癌市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按藥物類別分類的全球前列腺癌市場成長機會
    • 全球前列腺癌市場成長機會（按分銷管道）
    • 全球前列腺癌市場按地區成長機會
  • 全球前列腺癌市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球前列腺癌市場的產能
    • 全球前列腺癌市場的合併、收購和合資企業
    • 認證和許可

第7章主要企業概況

  • Ferring Pharmaceuticals
  • Johnson & Johnson
  • Merck
  • Pfizer
  • Sanofi
  • AbbVie
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Clovis Oncology
簡介目錄

Prostate Cancer Trends and Forecast

The future of the global prostate cancer market looks promising with opportunities in the hospital pharmacies, drug store & retail pharmacies, and online pharmacies markets. The global prostate cancer market is expected to reach an estimated $19.47 billion by 2030 with a CAGR of 8.7% from 2024 to 2030. The major drivers for this market are growing incidence of prostate cancer driving the need for advanced prostate treatments, prostate cancer medications advancing through phase III clinical trials, and enhancing funding for research & development and advancements in treatment technology.

A more than 150-page report is developed to help in your business decisions.

Prostate Cancer by Segment

The study includes a forecast for the global prostate cancer by drug class, distribution channel, and region.

Prostate Cancer Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

  • Hormonal ADT
  • AR-Directed Therapies
  • Cytotoxic Agents
  • Bone Metastases
  • Therapeutic Vaccines
  • PARP Inhibitors
  • Kinase Inhibitors
  • PSMA-Targeted Radioligands

Prostate Cancer Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacies
  • Drug store & Retail Pharmacies
  • Online Pharmacies

Prostate Cancer Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Prostate Cancer Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies prostate cancer companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the prostate cancer companies profiled in this report include-

  • Ferring Pharmaceuticals
  • Johnson & Johnson
  • Merck
  • Pfizer
  • Sanofi
  • Abbvie
  • Astellas Pharma
  • Astrazeneca
  • Bayer
  • Clovis Oncology
  • Dendreon Pharmaceuticals

Prostate Cancer Market Insights

Lucintel forecasts that AR-directed therapies is expected to witness highest growth over the forecast period.

APAC is expected to witness highest growth over the forecast period due to The increasing prevalence of prostate cancer, the availability of several treatment choices, technical developments, customized medications, and affordable therapy.

Features of the Global Prostate Cancer Market

Market Size Estimates: Prostate cancer market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Prostate cancer market size by drug class, distribution channel, and region in terms of value ($B).

Regional Analysis: Prostate cancer market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug class, distribution channel, and regions for the prostate cancer market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the prostate cancer market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the prostate cancer market size?

Answer: The global prostate cancer market is expected to reach an estimated $19.47 billion by 2030.

Q.2 What is the growth forecast for prostate cancer market?

Answer: The global prostate cancer market is expected to grow with a CAGR of 8.7% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the prostate cancer market?

Answer: The major drivers for this market are growing incidence of prostate cancer driving the need for advanced prostate treatments, prostate cancer medications advancing through phase III clinical trials, and enhancing funding for research & development and advancements in treatment technology.

Q4. What are the major segments for prostate cancer market?

Answer: The future of the prostate cancer market looks promising with opportunities in the hospital pharmacies, drug store & retail pharmacies, and online pharmacies markets.

Q5. Who are the key prostate cancer market companies?

Answer: Some of the key prostate cancer companies are as follows.

  • Ferring Pharmaceuticals
  • Johnson & Johnson
  • Merck
  • Pfizer
  • Sanofi
  • AbbVie
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Clovis Oncology

Q6. Which prostate cancer market segment will be the largest in future?

Answer: Lucintel forecasts that ar-directed therapies is expected to witness highest growth over the forecast period.

Q7. In prostate cancer market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness highest growth over the forecast period due to The increasing prevalence of prostate cancer, the availability of several treatment choices, technical developments, customized medications, and affordable therapy

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the prostate cancer market by drug class (hormonal ADT, AR-directed therapies, cytotoxic agents,bone metastases, therapeutic vaccines, PARP inhibitors, kinase inhibitors, and PSMA-targeted radioligands), distribution channel (hospital pharmacies, drug store & retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Prostate Cancer Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Prostate Cancer Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Prostate Cancer Market by Drug Class
    • 3.3.1: Hormonal ADT
    • 3.3.2: AR-Directed Therapies
    • 3.3.3: Cytotoxic Agents
    • 3.3.4: Bone Metastases
    • 3.3.5: Therapeutic Vaccines
    • 3.3.6: PARP Inhibitors
    • 3.3.7: Kinase Inhibitors
    • 3.3.8: PSMA-Targeted Radioligands
  • 3.4: Global Prostate Cancer Market by Distribution Channel
    • 3.4.1: Hospital Pharmacies
    • 3.4.2: Drug store & Retail Pharmacies
    • 3.4.3: Online Pharmacies

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Prostate Cancer Market by Region
  • 4.2: North American Prostate Cancer Market
    • 4.2.2: North American Prostate Cancer Market by Distribution Channel: Hospital Pharmacies, Drug store & Retail Pharmacies, and Online Pharmacies
  • 4.3: European Prostate Cancer Market
    • 4.3.1: European Prostate Cancer Market by Drug Class: Hormonal ADT, AR-Directed Therapies, Cytotoxic Agents, Bone Metastases, Therapeutic Vaccines ,PARP Inhibitors, Kinase Inhibitors, and PSMA-Targeted Radioligands
    • 4.3.2: European Prostate Cancer Market by Distribution Channel: Hospital Pharmacies, Drug store & Retail Pharmacies, and Online Pharmacies
  • 4.4: APAC Prostate Cancer Market
    • 4.4.1: APAC Prostate Cancer Market by Drug Class: Hormonal ADT, AR-Directed Therapies, Cytotoxic Agents, Bone Metastases, Therapeutic Vaccines ,PARP Inhibitors, Kinase Inhibitors, and PSMA-Targeted Radioligands
    • 4.4.2: APAC Prostate Cancer Market by Distribution Channel: Hospital Pharmacies, Drug store & Retail Pharmacies, and Online Pharmacies
  • 4.5: ROW Prostate Cancer Market
    • 4.5.1: ROW Prostate Cancer Market by Drug Class: Hormonal ADT, AR-Directed Therapies, Cytotoxic Agents, Bone Metastases, Therapeutic Vaccines ,PARP Inhibitors, Kinase Inhibitors, and PSMA-Targeted Radioligands
    • 4.5.2: ROW Prostate Cancer Market by Distribution Channel: Hospital Pharmacies, Drug store & Retail Pharmacies, and Online Pharmacies

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Prostate Cancer Market by Drug Class
    • 6.1.2: Growth Opportunities for the Global Prostate Cancer Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Prostate Cancer Market by Region
  • 6.2: Emerging Trends in the Global Prostate Cancer Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Prostate Cancer Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Prostate Cancer Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Ferring Pharmaceuticals
  • 7.2: Johnson & Johnson
  • 7.3: Merck
  • 7.4: Pfizer
  • 7.5: Sanofi
  • 7.6: AbbVie
  • 7.7: Astellas Pharma
  • 7.8: AstraZeneca
  • 7.9: Bayer
  • 7.10: Clovis Oncology